34 patients who suffered from NVG, excluding patients with shallow anterior chamber.All patients were assigned to groups A and B according the different therapy.Group A ( 15 eyes ) was treated with Ex -PRESS glaucoma filtration device implantation. Group B ( 19 eyes ) underwent a trabeculectomy combined with mitomycin C. All the patients were followed up to 1a.The results of best-corrected visual acuity ( BCVA ) , intraocular pressure ( lOP ) , the combination of lOP lowering medications, complications were recorded statistically analyzed preoperative and 1d, 1, 4wk, 6 and 12mo after operation. · RESULTS: Mean lOP decreased significantly frompreoperative values in both groups ( P=0.01 ) .The both group had similar lOP values changes after 1, 4wk, 6, 12mo, and there were no significant difference in statistics (P=0.451).There was no significant difference in BCVA changes after operation in both groups ( P =0.832).Success rate was 66.7%and 63.1%at 1a after Ex-PRESS glaucoma filtration device and trabeculectomy, respectively. Anterior chamber bleeding occurred to 8 cases after trabeculectomy in group B and to 3 cases with Ex-PRESS glaucoma filtration device implantation in group A.Choroidal detachment occurred to 3 cases in
group A and 6 cases in group B. No other ocular or systemic adverse events were found during the follow-up duration.
·CONCLUSlON:ln the short-term, Ex-PRESS glaucoma filtration device implantation has the advantages of simpleness, safety, minimally invasive, short learning curve for neovascular glaucoma, which provides us an available strategy to conquer NVG by simply operation and less suffering.

AIM: To investigate therapeutic effects of combination therapy for neovascular glaucoma ( NVG) .
METHODS: This retrospective study comprised 34 eyes of 34 patients who suffered from NVG. All patients were assigned to group A, B, C and D according to the different combination therapies. Group A ( 11 eyes of 11 patients ) was treated with intravitreal injection of ranibizumab and panretinal photocoagulation ( PRP ) . Group B ( 10 eyes of 10 patients ) was treated with transcleral cyclophotocoagulation and PRP. Group C ( 6 eyes of 6 patients) was treated with 3 therapies together. Group D (7 eyes of 7 patients) was treated with 810nm transcleral cyclophotocoagulation and soft gas-permeable contact lenses. All the patients were followed-up for 1a. The best- corrected visual acuity ( BCVA ) , intraocular pressure ( IOP ) were recorded and analyzed prior to operation and 1, 4wk, 6 and 12mo after operation.
RESULTS: All the post treatment IOP decreased significantly ( P<0. 05 ) from the values before therapy, and the IOP values after 4wk, 6, 12mo were not significantly different ( P > 0. 05 ) in statistics. Most patients' IOP can be controlled below 23mmHg after combination therapy. The visual acuity in group A after 1, 4wk, 6mo compared with those before treatment was significantly increased ( P<0. 05 ) in statistics and other groups did not significantly change before and after treatment (P>0. 05). Anterior chamber bleeding occurred to 2 cases after 1wk of transcleral cyclophotocoagulation. No other ocular or systemic adverse events were found during the follow-up duration.
CONCLUSION: After the combination of intraocular injection of the anti - VEGF drugs, 810nm laser cyclophotocoagulation and PRP, most patients with NVG disease can be effectively treated, can effectively control IOP, and retain part of the visual function, significantly improve the quality of life. In the short - term, combination therapy is safe and effective for NVG, which provides us an available strategy to conquer NVG by simply programmable operation and less suffering.

Objective: To study the methylation status of PTPRO (protein tyrosine phosphatase receptor-type O) gene as a potential biomarker in the detection of breast cancer, and to analyze its association with clincopathologic features. Methods: The PTPRO gene promoter methylation status in primary human breast tumors, normal breast tissues and peripheral blood were detected by MSP (methylation specific-PCR), and the results were analyzed with corresponding clinico pathological data. Results: The frequency of PTPRO gene mehtylation among 98 breast cancer tissues were 55.1% (54/98), and 33.7% (33/98) in peripheral blood, however no PTPRO gene mehtylation was found in normal breast tissues. PTPRO gene methylation in peripheral blood was significantly correlated to that in tumor tissue (r = 17.083,P = 0.000). PTPRO methylation was associated with tumor stage (r = 9.649,P = 0.001), histological grade (r = 2.476,P = 0.035), lymph node metastasis (r = 3.400, P = 0.003) and ErbB2-positive (r = 4.912,P = 0.000). Patients with ER (estrogen receptor)-negative and PR (progestogen receptor)-negative had more PTPRO methylation, but the difference was not statistically significant. No aberrant methylation of PTPRO gene was found in the plasma samples from healthy control and the patients without gene methylation in tumor tissues. Conclusion: PTPRO gene promoter mehtylation may play an important role in the carcinogenesis and development of breast cancer. It might be used to predict the prognosis of breast cancer patients. Furthermore, this is the first report of methylated PTPRO as a noninvasive tumor biomarker in peripheral blood of breast tumor patients for detection and disease monitoring. Copyright © 2013 by TUMOR.

Objective To evaluate the influence of different field-strength magnets(1.5 T and 3.0 T)on MRI artifacts caused by Ni-Cr alloy fixed prostheses.Methods The crown,bridge and upper denture fixed prostheses with different thickness were produced by Ni-Cr alloy as test samples,and were one by one put on the centre of water phantom for MR scanning with different field-strength magnets(1.5 T and 3.0 T).The artifact areas on these two field-strength magnets were measured and statistically compared.The plastic prostheses with the same shape and thickness as the test samples were served as controls.Results Ni-Cr alloy fixed prostheses could cause MRI artifacts,and the artifact areas increased with the mass of prostheses.However,no artifact area was found in controls.Compared with those on 1.5 T magnet,the MRI artifact areas significantly increased on 3.0 T magnet(P

Adult ; China ; Female ; Humans ; Occupational Health Services ; Women's Health Services ; Young Adult

Objective To evaluate the relationship between the ratio of the maximal value of the H-reflex to the maximal value of the M response (Hmax/Mmax), the ratio of the developmental slope of the H-reflex to the slope of the M response (Hslp/Mslp), and the ratio of the threshold of the H-reflex to the threshold of the M response (Hth/Mth) and upper-extremity spasticity in stroke patients. Methods Upper-extremity spasticity in 34 stroke patients was assessed by modified Ashworth Scale (MAS). H-reflex was recorded in flexor carpi radialis muscle on both sides. Hmax/Mmax, Hslp/Mslp and Hth/Mth in the spastic side were compared to the unaffected side. Results The mean of Hmax/Mmax (spastic side, 0.36±0.17; unaffected side, 0.14±0.07) and Hslp/Mslp (spastic side, 0.72±0.40; unaffected side, 0.26±0.22) showed significant difference between 2 sides (P<0.05). The mean of Hth/Mth (spastic side, 0.93±0.14; unaffected side, 0.98±0.12) showed no significant difference (P>0.05). Hmax/Mmax and Hslp/Mslp were correlated positively with score of MAS in the stroke patients (r=0.608, P<0.05; r=0.917, P<0.05), while there was no correlation between Hth/Mth and score of MAS (r=-0.128, P>0.05). Conclusion Hmax/Mmax and Hslp/Mslp could be sensitive electrophysiologic parameters to evaluate upper-extremity spasticity after stroke.

Adult ; Electromyography ; Gasoline ; poisoning ; Humans ; Male ; Poisoning ; physiopathology ; psychology ; Young Adult

OBJECTIVETo observe the short-term and long-term efficacies on primary dysmenorrhea treated with staging acupoint embedment therapy.

METHODSSeventy cases of primary dysmenorrhea were randomized into an embedment therapy group and a fenbid group, 35 cases in each one. In the embedment therapy group, the embedment therapy was applied twice during the menstrual cycle, one treatment 3 days before menstruation and one treatment during the 12th-14th days of menstruation, respectively. Guanyuan (CV 4), Zigong (EX-CA 1), Diji (SP 8) and Ciliao (BL 32) were the main acupoints in the treatment 3 days before menstruation. Shenshu (BL 23), Ganshu (BL 18) and Pishu (BL 20) were the main acupoints in the treatment during menstruation. In the fenbid group, fenbid was prescribed for oral administration, 0.3 g each time, twice a day, starting 3 days before menstruation till pain was relieved. The treatment of one menstrual cycle was one session. The continuous treatment of 3 menstrual cycles was required. The short-term and long-term efficacies were evaluated at the end of the 3rd cycle and in 3 months after the treatment terminal. The dysmenorrhea score was used to evaluate the efficacy. Visual analogue scale (VAS) and SF-36 were for the assessment of pain degree and life quality.

RESULTS(1) The total effective rate was 91.4% (32/35) in the embedment therapy group after the 3 menstrual cycles, which was better than 74.3% (26/35) in the fenbid group (P < 0.01). In the follow-up stage, the total effective rate was 91.4% (32/35) in the embedment therapy group, which was better than 40.0% (14/35) in the fenbid group (P < 0.01). (2) The differences were not significant in dysmenorrhea score and VAS score after the 1st and 2nd menstrual cycle treatments between the two groups (all P > 0.05). In the 3rd menstrual cycle and the follow-up stage, the dysmenorrhea score and VAS score were reduced obviously in the embedment therapy group as compared with those in the fenbid group (P < 0.05, P < 0.01). The rebound effect occurred in the follow-up stage in the fenbid group. (3) In the 3rd menstrual cycle and the follow-up stage, the improvement in the total score of life quality of the embedment therapy group was superior apparently to the fenbid group (P < 0.05, P < 0. 01).

CONCLUSIONThe staging acupoint embedment therapy achieves the superior short-term and long-term efficacies as compared with the oral administration of fenbid in the treatment of primary dysmenorrhea. As the symptoms of dysmenorrhea and pain are relieved, the life quality is improved.

Acupuncture Points ; Acupuncture Therapy ; instrumentation ; Adolescent ; Adult ; Catgut ; utilization ; Dysmenorrhea ; therapy ; Female ; Humans ; Pain Measurement ; Treatment Outcome ; Young Adult

Biofilms ; Biomedical Research ; DNA, Bacterial

Anti-Inflammatory Agents ; pharmacology ; Brain ; drug effects ; metabolism ; Humans ; NF-kappa B ; metabolism ; Neurons ; drug effects ; metabolism ; Tumor Necrosis Factor-alpha ; metabolism ; alpha-MSH ; pharmacology